SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Palvella Therapeutics Reports Q3 Results; FDA Accepts QTORIN NDA

Palvella Therapeutics said the FDA accepted its NDA for QTORIN™ Rapamycin and granted priority review for microcystic lymphatic malformation.

PVLA

Story updates

12:33:01 PM UTC
SquawkNews
FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic Malformations, a Serious, Rare Lifelong Disease Affecti…
12:33:05 PM UTC
SquawkNews
The FDA accepted Palvella's NDA for QTORIN rapamycin for microcystic lymphatic malformations and granted Priority Review, setting a PDUFA target action date of February 28, 2027. The company reported $236.7M in cash, cash equivalents and short-term investments as of September 30, 2026; no prior-per…

Related stories